Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D. T. Ugrekhelidze"'
Autor:
A. A. Svistunov, R. I. Yagudina, G. T. Abdrashitova, V. V. Babiy, E. I. Makarova, A. A. Pochuprina, Yu. V. Rybchenko, G. A. Tolordava, D. T. Ugrekhelidze
Publikováno v:
Сеченовский вестник, Vol 0, Iss 2, Pp 42-50 (2022)
This article describes pharmacoeconomic analysis methods of which follow themodern requirements to this type of health technology assessment. Special attention is paid to the adaptation of pharmacoeconomic analysis methods to a specific nosology. Th
Externí odkaz:
https://doaj.org/article/b6510872156849b6a5a31ce11423e170
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 27-33 (2020)
The Government Decree, approved in December 2019, required registration certificates holders of reference drugs, included in the essential drug list (EDL), submit applications for mandatory price re-registration. Drugs included in the high-cost nosol
Externí odkaz:
https://doaj.org/article/b1921c689d4d49a28a6653641e88895d
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 3, Pp 60-64 (2018)
Cerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation
Externí odkaz:
https://doaj.org/article/d4dcdecbbcf04a1fa1ec9b6d81c363e2
Publikováno v:
Фармакоэкономика, Vol 6, Iss 3, Pp 3-9 (2015)
Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most of utility researches are conducted using standard gamble method which is considered the classic instrument of health state utilities assessment. This article p
Externí odkaz:
https://doaj.org/article/3b9a7b9ffd58432fa7298ac97a68aef1
Publikováno v:
Kachestvennaya klinicheskaya praktika. :27-33
The Government Decree, approved in December 2019, required registration certificates holders of reference drugs, included in the essential drug list (EDL), submit applications for mandatory price re-registration. Drugs included in the high-cost nosol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e14a60181fe23c8b75e44cd79d16e6c
https://doi.org/10.37489/2588-0519-2020-3-27-33
https://doi.org/10.37489/2588-0519-2020-3-27-33